<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21848" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fluorouracil</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Casale</surname>
            <given-names>Jarett</given-names>
          </name>
          <aff>Campbell University School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jarett Casale declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21848.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fluorouracil, also known as 5-fluorouracil or 5-FU, belongs to the class of chemotherapy drugs used to treat various neoplasms.&#x000a0;Systemic fluorouracil is approved by the US Food and Drug Administration (FDA) for the treatment of gastric adenocarcinoma, pancreatic adenocarcinoma, breast adenocarcinoma, and colorectal adenocarcinoma. In addition, topical fluorouracil (5%) is FDA-approved for managing dermatologic conditions such as multiple actinic or solar keratoses and superficial basal cell carcinomas in cases where alternative methods are not feasible.&#x000a0;Off-label uses of systemic fluorouracil include anal carcinoma, advanced biliary tract carcinoma, cervical cancer, and esophageal cancer.</p>
        <p>Upon ingestion or topical application, fluorouracil enters cells through a facilitated transport mechanism and undergoes conversion into fluorodeoxyuridine monophosphate (FdUMP). FdUMP then forms complexes with the enzyme thymidylate synthase, thereby inhibiting the production of deoxythymidine monophosphate (dTMP). As dTMP is crucial for DNA replication and repair, its depletion causes an imbalance in intracellular nucleotides, ultimately resulting in the generation of double-stranded DNA breaks facilitated by the enzyme endonuclease. This activity outlines the indications, mechanism of action, and contraindications of fluorouracil as a valuable agent for treating a spectrum of visceral and dermatologic malignancies.&#x000a0;This activity particularly emphasizes the adverse event profile and other significant factors of fluorouracil, such as off-label uses, highlighting the crucial and collaborative efforts of the interprofessional healthcare team in the management of various malignancies.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate patient populations for fluorouracil therapy based on indications approved by the FDA.</p></list-item><list-item><p>Implement proper dosage adjustments and administration techniques for fluorouracil based on individual patient factors.</p></list-item><list-item><p>Apply evidence-based guidelines and clinical protocols to guide decision-making regarding the use of fluorouracil in various neoplastic conditions.</p></list-item><list-item><p>Collaborate with interprofessional healthcare team members to optimize patient care and safety during fluorouracil treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21848&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21848">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21848.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fluorouracil,&#x000a0;also known as 5-fluorouracil or 5-FU, belongs to the class of chemotherapy drugs used to treat various neoplasms.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Systemic&#x000a0;fluorouracil is approved by the US Food and Drug Administration (FDA) for treating gastric adenocarcinoma, pancreatic adenocarcinoma, breast adenocarcinoma, and colorectal adenocarcinoma.<xref ref-type="bibr" rid="article-21848.r1">[1]</xref> In addition, topical fluorouracil (5%) is FDA-approved for managing dermatologic conditions such as multiple actinic or solar keratoses and superficial basal cell carcinomas in cases where alternative methods are not feasible.<xref ref-type="bibr" rid="article-21848.r2">[2]</xref>&#x000a0;</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Off-label uses of systemic fluorouracil include anal carcinoma, advanced biliary tract carcinoma, cervical cancer, and esophageal cancer.<xref ref-type="bibr" rid="article-21848.r3">[3]</xref><xref ref-type="bibr" rid="article-21848.r4">[4]</xref><xref ref-type="bibr" rid="article-21848.r5">[5]</xref><xref ref-type="bibr" rid="article-21848.r6">[6]</xref>&#x000a0;According to the&#x000a0; American Society of Clinical Oncology (ASCO), treatment with fluorouracil is suggested for treating nasopharyngeal carcinoma.<xref ref-type="bibr" rid="article-21848.r7">[7]</xref>&#x000a0;The&#x000a0;management protocol for muscle-invasive bladder cancer (endorsed by the American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology) involves employing the radiation-sensitizing chemotherapy regimen comprising fluorouracil/cisplatin and mitomycin-C.<xref ref-type="bibr" rid="article-21848.r8">[8]</xref></p>
        <p>Off-label uses of topical fluorouracil are metastatic cutaneous lesions from melanoma, keratoacanthomas, and treatment-resistant vitiligo. Evidence suggests that a conventional 4-week course of fluorouracil applied to the face and ears can be considered for reducing squamous cell carcinoma in high-risk individuals. Other dermatologic uses of fluorouracil include the reduction of keloids and hypertrophic scars.<xref ref-type="bibr" rid="article-21848.r9">[9]</xref><xref ref-type="bibr" rid="article-21848.r10">[10]</xref></p>
      </sec>
      <sec id="article-21848.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Upon ingestion or topical application, fluorouracil enters cells through a facilitated transport mechanism and undergoes conversion into fluorodeoxyuridine monophosphate (FdUMP). FdUMP then forms complexes with the enzyme thymidylate synthase, thereby inhibiting the production of deoxythymidine monophosphate (dTMP). As dTMP is crucial for DNA replication and repair, its depletion causes an imbalance in intracellular nucleotides, ultimately resulting in the generation of double-stranded DNA breaks facilitated by the enzyme endonuclease.<xref ref-type="bibr" rid="article-21848.r11">[11]</xref></p>
        <p>In addition to inhibiting thymidylate synthase, fluorouracil also serves as a pyrimidine analog by misincorporating into RNA and DNA instead of uracil or thymine. The overwhelming damage of DNA repair machinery caused by these mechanisms ultimately results in cell death of rapidly proliferating cells. The topical use of fluorouracil has a selective cytotoxic effect on actinic skin, leaving normal skin unaffected. The proposed mechanism for this phenomenon is selective inhibition of thymidylate synthase in actinic skin and only partial inhibition in normal skin.<xref ref-type="bibr" rid="article-21848.r12">[12]</xref></p>
        <p>Fluorouracil exhibits other mechanisms of action, including interference with RNA processing and increasing p53 expression.<xref ref-type="bibr" rid="article-21848.r1">[1]</xref> The mechanism by which fluorouracil increases p53 expression may be concurrently responsible for its efficacy in treating dermatologic conditions with altered p53 expression, including actinic keratosis and squamous cell carcinoma.<xref ref-type="bibr" rid="article-21848.r12">[12]</xref>&#x000a0;The resistance mechanism against fluorouracil is the upregulation of&#x000a0;dihydropyrimidine dehydrogenase (DPD) gene expression.<xref ref-type="bibr" rid="article-21848.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Fluorouracil is a water-soluble drug administered intravenously (IV). After&#x000a0;IV administration of fluorouracil, it rapidly enters cells. Following topical administration, approximately 6% of the dose is absorbed in the systemic circulation.&#x000a0;Fluorouracil poorly penetrates normal skin cells, which are less sensitive to fluorouracil than&#x000a0;rapidly proliferating cells.<xref ref-type="bibr" rid="article-21848.r1">[1]</xref></p>
        <p><bold>Distribution:</bold> After parental administration, fluorouracil is distributed throughout the body, including the intestinal mucosa, bone marrow, liver, and CNS.&#x000a0;</p>
        <p><bold>Metabolism:</bold>&#x000a0;Fluorouracil is&#x000a0;rapidly metabolized in the liver to active metabolites FdUMP, fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine triphosphate (FUTP).&#x000a0;Fluorouracil undergoes catabolism to dihydro-fluorouracil (DHFU), an inactive metabolite, mediated by DPD, which is predominantly found in the liver, intestinal mucosa, and various other tissues.<xref ref-type="bibr" rid="article-21848.r14">[14]</xref><xref ref-type="bibr" rid="article-21848.r15">[15]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Fluorouracil is eliminated primarily in the urine as metabolites. Approximately 5% to 20% of the fluorouracil is excreted unchanged in the urine.<xref ref-type="bibr" rid="article-21848.r16">[16]</xref></p>
      </sec>
      <sec id="article-21848.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Fluorouracil exhibits poor absorption in the gastrointestinal tract when administered orally. Parenteral administration of fluorouracil is preferable when treating visceral malignancies to optimize systemic bioavailability.&#x000a0;Fluorouracil can be administered via&#x000a0;IV bolus, continuous&#x000a0;IV infusion over several days, and 'protracted' infusion via an ambulatory pump for&#x000a0;1 to&#x000a0;2 weeks. When given IV, the terminal half-life of fluorouracil is around 8 to 20 minutes due to rapid catabolism in the liver.<xref ref-type="bibr" rid="article-21848.r17">[17]</xref></p>
        <p>Fluorouracil&#x000a0;can also be applied topically in solutions or creams with strengths varying from 0.5% to 5% when the desired clinical use is for dermatologic conditions. Systemic absorption of topical fluorouracil has been studied to range from less than 2% to 6% but can be up to 75 times greater if applied to diseased skin. In addition to topical fluorouracil for dermatologic conditions, intralesional delivery is also useful for various conditions. Further studies are necessary to determine the systemic absorption of intralesionally delivered fluorouracil.<xref ref-type="bibr" rid="article-21848.r10">[10]</xref><xref ref-type="bibr" rid="article-21848.r12">[12]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Some&#x000a0;general dosing regimens follow based on indications. However, clinicians should refer to institutional protocols and the package inserts for specific dosing, including toxicity-related dose adjustments. Alternative regimens for some conditions are also available.</p>
        <list list-type="bullet">
          <list-item>
            <p>Breast cancer: 500 mg/m<sup>2 </sup>per dose IV for a single dose on days 1 and 8 of a 28-day cycle.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastric&#x000a0;cancer
<list list-type="bullet"><list-item><p>Resectable disease: 200 mg/m<sup>2</sup>/24 h IV infusion on days 1 to 21 of a 21-day cycle. Use fluorouracil with cisplatin as part of a multi-drug chemotherapy regimen.</p></list-item><list-item><p>Advanced disease: 750 to 1000 mg/m<sup>2</sup>/24 h IV infusion on days 1 to 4 of a 28-day cycle. Use with cisplatin.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Colorectal&#x000a0;cancer
<list list-type="bullet"><list-item><p>Infusion regimen: 400 mg/m<sup>2</sup>/dose IV for a single dose on day 1, then 1200 to 1500 mg/m<sup>2</sup>/24 h IV infusion on days 1 and 2 of a 14-day regimen. Use with leucovorin with or without irinotecan or oxaliplatin.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pancreatic cancer: 400 mg/m<sup>2</sup>/dose IV on the first day,&#x000a0;then 1200 mg/m<sup>2</sup>/24 h IV infusion on days 1 and 2 of a 14-day cycle. Give for 12 cycles as part of a multi-drug chemotherapy regimen.</p>
          </list-item>
        </list>
        <p>For topical fluorouracil, dosing regimens include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Actinic keratosis: Apply the solution or 5% cream twice daily for 2 to 4 weeks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Superficial basal cell carcinoma: Apply the 5% cream twice daily for 3 to 6 weeks. According to the American Association of Dermatology guidelines, monotherapy with topical fluorouracil is advised&#x000a0;for small tumors at low-risk locations&#x000a0;and&#x000a0;adverse effects to standard therapy.<xref ref-type="bibr" rid="article-21848.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No information is provided in the manufacturer's product labeling; however, fluorouracil is not advised in severe hepatic impairment.<xref ref-type="bibr" rid="article-21848.r19">[19]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;Renal impairment requires no dosing adjustments, although hemodialysis patients should reduce their dose by 50% on dialysis days. Patients with renal impairment are at risk for hyperammonemia.<xref ref-type="bibr" rid="article-21848.r20">[20]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Fluorouracil is an FDA pregnancy category D drug use that should be avoided in pregnancy due to the risk of teratogenicity. Topical fluorouracil during pregnancy is associated with ventricular septal defect and an increased risk of miscarriage. The risk of teratogenicity is highest during the first trimester.&#x000a0;Fluorouracil is relatively safe during the second and third trimesters of pregnancy. However, ESMO (European Society for Medical Oncology) guidelines suggest a 3-week&#x000a0;duration between the last chemotherapy&#x000a0;session and the&#x000a0;estimated delivery date; consequently, chemotherapy&#x000a0;is not recommended beyond&#x000a0;33 weeks of gestation. However, clinicians should also evaluate&#x000a0;the possible benefits to the&#x000a0;patient against the risks to the fetus.<xref ref-type="bibr" rid="article-21848.r21">[21]</xref><xref ref-type="bibr" rid="article-21848.r22">[22]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Systemic fluorouracil is contraindicated during breastfeeding. Topical fluorouracil can be&#x000a0;used as it has insignificant risk if&#x000a0;applied precisely. Patients&#x000a0;should be&#x000a0;counseled&#x000a0;not to apply fluorouracil cream to the breast or nipple. In addition, the infant's skin should not have direct contact with the sites of skin treated by fluorouracil. However, the manufacturer's labeling recommends cessation of nursing or discontinuation of topical fluorouracil treatment after thoroughly evaluating the risk-benefit analysis.<xref ref-type="bibr" rid="article-21848.r23">[23]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;According to the manufacturer labeling, safety and efficacy have not been confirmed for pediatric use. However, fluorouracil is used in hepatoblastoma and nasopharyngeal carcinoma.<xref ref-type="bibr" rid="article-21848.r24">[24]</xref><xref ref-type="bibr" rid="article-21848.r25">[25]</xref><xref ref-type="bibr" rid="article-21848.r26">[26]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;A comprehensive geriatric assessment (CGA) should be considered. CGA's primary components include the patients' functional status, associated comorbidities, polypharmacy, cognition, and nutritional status. Specific interventions and treatment should be&#x000a0;provided&#x000a0;to manage the health problems recognized on CGA, which can decrease&#x000a0;adverse drug reactions and&#x000a0;increase the&#x000a0;likelihood of completing scheduled chemotherapy without&#x000a0;dose alteration.<xref ref-type="bibr" rid="article-21848.r27">[27]</xref></p>
      </sec>
      <sec id="article-21848.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Fluorouracil&#x000a0;has many adverse drug&#x000a0;reactions when used systemically. Diarrhea was the most common adverse effect reported in patients receiving systemic fluorouracil treatment. Clinicians should withhold fluorouracil for severe diarrhea until it is resolved. Other common adverse effects include vomiting, nausea, and dehydration.</p>
        <p>More concerning&#x000a0;adverse effects that require monitoring in patients receiving systemic fluorouracil chemotherapy include neutropenia, pyrexia, pulmonary embolism, thrombocytopenia, and leukopenia. Leukopenia, leading to an immunocompromised state in these patients, can result in secondary pneumonia or sepsis.<xref ref-type="bibr" rid="article-21848.r28">[28]</xref><bold>&#x000a0;</bold>Drug-induced subacute cutaneous lupus erythematosus (SCLE) has been reported with systemic fluorouracil with positive anti-Ro (SSA antibody).<xref ref-type="bibr" rid="article-21848.r29">[29]</xref></p>
        <p>The systemic&#x000a0;adverse&#x000a0;effect profile of topically applied fluorouracil is minimal due to limited absorption. The most common adverse effect of the topical application of fluorouracil is localized skin irritation, leading to ulceration and predisposing patients to infection. Other&#x000a0;adverse effects of topical fluorouracil therapy include pruritis, pain, erythema, crusting, eschar, and eczematous skin reactions.<xref ref-type="bibr" rid="article-21848.r1">[1]</xref><xref ref-type="bibr" rid="article-21848.r2">[2]</xref><xref ref-type="bibr" rid="article-21848.r18">[18]</xref></p>
        <p>Severe adverse drug reactions and their management are described below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiotoxicity:&#x000a0;Fluorouracil can cause angina, myocardial infarction, and heart failure. Infusional regimens of fluorouracil have greater risk compared with bolus regimens.&#x000a0;Withhold fluorouracil for cardiac toxicity. Fluorouracil-induced vasospasm is treated with&#x000a0;nitrates or calcium channel blockers.<xref ref-type="bibr" rid="article-21848.r30">[30]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyperammonemic encephalopathy: Clinical features include altered mental status without radiologic abnormality and elevated ammonia levels within 72 hours of initiation of fluorouracil.&#x000a0;Discontinuation of fluorouracil is recommended. No definitive treatment currently exists; supportive care should be provided&#x000a0;via IV fluids, lactulose, and&#x000a0;branched-chain amino acids.<xref ref-type="bibr" rid="article-21848.r31">[31]</xref><xref ref-type="bibr" rid="article-21848.r32">[32]</xref><xref ref-type="bibr" rid="article-21848.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neurologic toxicity:&#x000a0;Fluorouracil can induce acute cerebellar syndrome, ataxia, seizures, and coma. Withhold fluorouracil for neurologic toxicity.<xref ref-type="bibr" rid="article-21848.r34">[34]</xref><xref ref-type="bibr" rid="article-21848.r35">[35]</xref><xref ref-type="bibr" rid="article-21848.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hand-foot syndrome:&#x000a0;Fluorouracil can cause&#x000a0;palmoplantar dysesthesia, numbness, burning sensation, and symmetric erythema. Desquamation, blistering, and&#x000a0;ulceration&#x000a0;are seen in severe cases. Discontinuation of fluorouracil is required in severe cases, and chemotherapy should be&#x000a0;restarted&#x000a0;at a reduced dose after remission.<xref ref-type="bibr" rid="article-21848.r37">[37]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mucositis:&#x000a0;Fluorouracil can cause severe mucositis. Discontinuation of fluorouracil is recommended until mucositis is resolved or decreased. Dose reduction is suggested. Oral cryotherapy&#x000a0;has been shown&#x000a0;to reduce oral mucositis in&#x000a0;patients receiving fluorouracil.<xref ref-type="bibr" rid="article-21848.r38">[38]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interaction</bold>
</p>
        <p>Fluorouracil&#x000a0;and its metabolites inhibit CYP2C19, and concurrent administration with warfarin can prolong the increase&#x000a0;in prothrombin time (PT/INR).<xref ref-type="bibr" rid="article-21848.r39">[39]</xref></p>
      </sec>
      <sec id="article-21848.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to treatment with fluorouracil include patients with a documented deficiency of the enzyme DPD. This enzyme degrades over 80% of 5-FU to biologically inactive metabolites and deficiency can result in life-threatening toxicity.<xref ref-type="bibr" rid="article-21848.r12">[12]</xref>&#x000a0;</p>
        <p>As discussed above, breastfeeding is also a contraindication&#x000a0;of systemic fluorouracil treatment. However, some studies suggest that intermittent therapy can be performed safely.<xref ref-type="bibr" rid="article-21848.r23">[23]</xref>&#x000a0;Fluorouracil has been shown to interact with many other pharmaceutical agents. Therefore, drug interactions should be checked before beginning treatment with fluorouracil.<xref ref-type="bibr" rid="article-21848.r17">[17]</xref></p>
      </sec>
      <sec id="article-21848.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Therapeutic drug monitoring of fluorouracil can be performed using high-performance liquid chromatography, gas chromatography-mass spectrometry, or immunoassay to measure plasma drug levels to reduce toxicity and improve efficacy. Therapeutic drug monitoring is essential for patients with DPD deficiency, in which fluorouracil treatment is the mainstay for their condition with no clinically efficacious alternatives.<xref ref-type="bibr" rid="article-21848.r40">[40]</xref></p>
        <p>Some studies suggest that DPD is inducible in deficient patients by using capecitabine, leading to new methods of fluorouracil chemotherapy titration in these individuals.<xref ref-type="bibr" rid="article-21848.r41">[41]</xref>&#x000a0;Complete blood count (CBC) should be monitored due to the risk of myelosuppression.<xref ref-type="bibr" rid="article-21848.r40">[40]</xref>&#x000a0;Liver function tests should be&#x000a0;routinely assessed due to the potential for hepatotoxicity.<xref ref-type="bibr" rid="article-21848.r42">[42]</xref></p>
      </sec>
      <sec id="article-21848.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>As described above, cardiotoxicity and neurotoxicity can be severe, requiring immediate cessation of fluorouracil treatment.&#x000a0;Patients experiencing severe adverse effects of fluorouracil treatment can be administered uridine triacetate within&#x000a0;4 days of fluorouracil treatment. Uridine triacetate is a pyrimidine analog composed of uridine triacetate. The mechanism of toxicity reversal is due to the high concentrations of uridine delivered by uridine triacetate that competes with fluorouracil metabolites for binding sites in the body. Uridine triacetate is administered orally, but whether&#x000a0;it is safe or efficacious after&#x000a0;4 days following fluorouracil administration is unknown.<xref ref-type="bibr" rid="article-21848.r43">[43]</xref><xref ref-type="bibr" rid="article-21848.r44">[44]</xref></p>
      </sec>
      <sec id="article-21848.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinical utilization of systemic fluorouracil therapy for the treatment of visceral malignancies has shown low efficacy due to various mechanisms of drug resistance. The overall response rate of advanced colorectal cancer to fluorouracil monotherapy is only 10%&#x000a0;to 15% and 40%&#x000a0;to 50% when combined with other chemotherapeutic agents. Many potential mechanisms of resistance to systemic fluorouracil treatment have been identified. They include altering drug influx and efflux pumps, drug target mutations, and enzyme activity alterations that reduce its clinical efficacy.</p>
        <p>Alterations in enzyme activity reducing clinical efficacy include overexpression of the target enzyme thymidylate synthase and increased DPD activity, resulting in increased drug catabolism. Identifying and targeting genes responsible for these resistance patterns using microarray technology can help guide future treatment strategies and improve the clinical efficacy of systemic fluorouracil chemotherapy. Some studies suggest that new encapsulated formulation technologies that alter drug absorption and bioavailability can overcome many common mechanisms for fluorouracil resistance.<xref ref-type="bibr" rid="article-21848.r11">[11]</xref></p>
        <p>Topical fluorouracil has a broad array of uses in the dermatological setting to treat various skin conditions.&#x000a0;This formulation is best known for its use as field therapy for treating&#x000a0;multiple actinic or solar keratoses to prevent progression to squamous cell carcinoma.<xref ref-type="bibr" rid="article-21848.r1">[1]</xref>&#x000a0;Randomized clinical trials have shown that chemoprevention therapy with 5% topical fluorouracil has reduced the incidence of squamous cell carcinomas in high-risk individuals and ultimately reduces the need for Mohs micrographic surgery in these patients.</p>
        <p>In addition to fluorouracil monotherapy, several topical combination therapies, including combination tretinoin, salicylic acid, and cryotherapy, have been studied to increase their clinical efficacy for reducing actinic keratoses. Topical fluorouracil has&#x000a0;been efficacious for improving photodamage in individuals. However, some studies found no significant aesthetic improvement when a conventional course was used in an&#x000a0;older male population.<xref ref-type="bibr" rid="article-21848.r45">[45]</xref><xref ref-type="bibr" rid="article-21848.r9">[9]</xref></p>
        <p>Intralesional fluorouracil has been studied as an effective method for treating keloids, hypertrophic scars, and keratoacanthomas. Studies suggest that combination therapy for keloids with intralesional fluorouracil and triamcinolone offers a prompt and productive treatment with a reduced adverse effect profile compared to each drug delivered individually.<xref ref-type="bibr" rid="article-21848.r10">[10]</xref> Intralesional fluorouracil can merit consideration when cutaneous malignancy is present in an anatomic area with poor wound healing capacity and where surgical intervention is undesirable, such as in the lower leg in&#x000a0;older individuals.<xref ref-type="bibr" rid="article-21848.r46">[46]</xref><xref ref-type="bibr" rid="article-21848.r47">[47]</xref></p>
        <p>Therapy with fluorouracil requires the efforts of an interprofessional team. The clinician or specialist should work with an oncology board-certified pharmacist to choose therapy, verify dosing, check for interactions, and counsel on adverse effects when prescribing drugs. Oncology-specialized nurses may administer the medication and monitor for treatment effectiveness and adverse reactions. All team members must exercise open lines of communication so that any issues&#x000a0;are addressed promptly.&#x000a0;The interprofessional healthcare team of physicians, advanced practice practitioners, oncologists, board-certified oncology pharmacists, and oncology-specialized nurses can improve treatment efficacy,&#x000a0;decrease&#x000a0;preventable adverse drug reactions, and optimize outcomes&#x000a0;related to fluorouracil therapy. Interprofessional coordination and collaboration&#x000a0;among&#x000a0;all team members, with shared decision-making, can enhance patient outcomes when using fluorouracil to treat cancers where it has efficacy.</p>
      </sec>
      <sec id="article-21848.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21848&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21848">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21848/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21848">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21848.s11">
        <title>References</title>
        <ref id="article-21848.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prince</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fathi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alkousakis</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Topical 5-fluorouracil in dermatologic disease.</article-title>
            <source>Int J Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>57</volume>
            <issue>10</issue>
            <fpage>1259</fpage>
            <page-range>1259-1264</page-range>
            <pub-id pub-id-type="pmid">30187924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jorizzo</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp.</article-title>
            <source>Skin Therapy Lett</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">11550079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodriguez-Bigas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vauthey</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ohinata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Crane</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.</article-title>
            <source>Oncotarget</source>
            <year>2014</year>
            <month>Nov</month>
            <day>30</day>
            <volume>5</volume>
            <issue>22</issue>
            <fpage>11133</fpage>
            <page-range>11133-42</page-range>
            <pub-id pub-id-type="pmid">25373735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valle</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Borbath</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Huguet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gruenberger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>D</given-names>
              </name>
              <collab>ESMO Guidelines Committee</collab>
            </person-group>
            <article-title>Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>suppl 5</issue>
            <fpage>v28</fpage>
            <page-range>v28-v37</page-range>
            <pub-id pub-id-type="pmid">27664259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zuo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Synergistic Cytotoxicity Effect of 5-Fluorouracil and SHP2 Inhibitor Demethylincisterol A3 on Cervical Cancer Cell.</article-title>
            <source>Anticancer Agents Med Chem</source>
            <year>2022</year>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>1313</fpage>
            <page-range>1313-1319</page-range>
            <pub-id pub-id-type="pmid">34238199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obermannov&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alsina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lordick</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Grieken</surname>
                <given-names>NCT</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smyth</surname>
                <given-names>EC</given-names>
              </name>
              <collab>ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org</collab>
            </person-group>
            <article-title>Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>992</fpage>
            <page-range>992-1004</page-range>
            <pub-id pub-id-type="pmid">35914638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Ismaila</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>MLK</given-names>
              </name>
              <name>
                <surname>Colevas</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>JTS</given-names>
              </name>
              <name>
                <surname>Whitley</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Yom</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>ATC</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AWM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.</article-title>
            <source>J Clin Oncol</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>840</fpage>
            <page-range>840-859</page-range>
            <pub-id pub-id-type="pmid">33405943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bochner</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dreicer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Michalski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Quale</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Zietman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Holzbeierlein</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.</article-title>
            <source>J Oncol Pract</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>621</fpage>
            <page-range>621-625</page-range>
            <pub-id pub-id-type="pmid">28796558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinstock</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thwin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Marcolivio</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Means</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Leader</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eilers</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Swetter</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Warshaw</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stricklin</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Dellavalle</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Sidhu-Malik</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Konnikov</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Werth</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Keri</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Robinson-Bostom</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ringer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>DiGiovanna</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>GD</given-names>
              </name>
              <collab>Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group</collab>
            </person-group>
            <article-title>Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.</article-title>
            <source>JAMA Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>154</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-174</page-range>
            <pub-id pub-id-type="pmid">29299592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prince</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fathi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alkousakis</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-280</page-range>
            <pub-id pub-id-type="pmid">29537445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>5-Fluorouracil: mechanisms of resistance and reversal strategies.</article-title>
            <source>Molecules</source>
            <year>2008</year>
            <month>Aug</month>
            <day>05</day>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>1551</fpage>
            <page-range>1551-69</page-range>
            <pub-id pub-id-type="pmid">18794772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ceilley</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>83</fpage>
            <page-range>83-9</page-range>
            <pub-id pub-id-type="pmid">21034289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>She</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shigdar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles.</article-title>
            <source>Nanoscale</source>
            <year>2015</year>
            <month>Sep</month>
            <day>07</day>
            <volume>7</volume>
            <issue>33</issue>
            <fpage>14080</fpage>
            <page-range>14080-92</page-range>
            <pub-id pub-id-type="pmid">26242620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Entezar-Almahdi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mohammadi-Samani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tayebi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Farjadian</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer.</article-title>
            <source>Int J Nanomedicine</source>
            <year>2020</year>
            <volume>15</volume>
            <fpage>5445</fpage>
            <page-range>5445-5458</page-range>
            <pub-id pub-id-type="pmid">32801699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghafouri-Fard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tondro Anamag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shoorei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fattahi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Javadinia</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Basiri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taheri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>658636</fpage>
            <pub-id pub-id-type="pmid">33954114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srinivas</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.</article-title>
            <source>Drug Dev Ind Pharm</source>
            <year>2016</year>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>945</fpage>
            <page-range>945-57</page-range>
            <pub-id pub-id-type="pmid">26467209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diasio</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of 5-fluorouracil.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>215</fpage>
            <page-range>215-37</page-range>
            <pub-id pub-id-type="pmid">2656050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Work Group</collab>
              <collab>Invited Reviewers</collab>
              <name>
                <surname>Kim</surname>
                <given-names>JYS</given-names>
              </name>
              <name>
                <surname>Kozlow</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olencki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of basal cell carcinoma.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>540</fpage>
            <page-range>540-559</page-range>
            <pub-id pub-id-type="pmid">29331385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krens</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Lassche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jansman</surname>
                <given-names>FGA</given-names>
              </name>
              <name>
                <surname>Desar</surname>
                <given-names>IME</given-names>
              </name>
              <name>
                <surname>Lankheet</surname>
                <given-names>NAG</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>van Herpen</surname>
                <given-names>CML</given-names>
              </name>
              <name>
                <surname>van Erp</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.</article-title>
            <source>Lancet Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>e200</fpage>
            <page-range>e200-e207</page-range>
            <pub-id pub-id-type="pmid">30942181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imamaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Funakoshi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kataoka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nishikawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Horimatsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yonezawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsubara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yanagita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>693</fpage>
            <page-range>693-699</page-range>
            <pub-id pub-id-type="pmid">33011861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Post</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Olin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Ngo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Van Loon</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary Management of Cancer During Pregnancy.</article-title>
            <source>JCO Oncol Pract</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>545</fpage>
            <page-range>545-557</page-range>
            <pub-id pub-id-type="pmid">32910882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peccatori</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Azim</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Orecchia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Pavlidis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kesic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pentheroudakis</surname>
                <given-names>G</given-names>
              </name>
              <collab>ESMO Guidelines Working Group</collab>
            </person-group>
            <article-title>Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>24 Suppl 6</volume>
            <fpage>vi160</fpage>
            <page-range>vi160-70</page-range>
            <pub-id pub-id-type="pmid">23813932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <chapter-title>Fluorouracil</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>5</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30000972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Current chemotherapeutic approaches for hepatoblastoma.</article-title>
            <source>Int J Clin Oncol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>955</fpage>
            <page-range>955-61</page-range>
            <pub-id pub-id-type="pmid">24052132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casanova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bisogno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gandola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cecchetto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Cataldo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Basso</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Indolfi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Favini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Collini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Potepan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>A</given-names>
              </name>
              <collab>Rare Tumors in Pediatric Age Group</collab>
            </person-group>
            <article-title>A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project.</article-title>
            <source>Cancer</source>
            <year>2012</year>
            <month>May</month>
            <day>15</day>
            <volume>118</volume>
            <issue>10</issue>
            <fpage>2718</fpage>
            <page-range>2718-25</page-range>
            <pub-id pub-id-type="pmid">21918965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez-Galindo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krailo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Krasin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McCarville</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pashankar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pappo</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>Dec</month>
            <day>10</day>
            <volume>37</volume>
            <issue>35</issue>
            <fpage>3369</fpage>
            <page-range>3369-3376</page-range>
            <pub-id pub-id-type="pmid">31553639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lund</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Vistisen</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bardal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dolin</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>R&#x000f8;nholt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO).</article-title>
            <source>Br J Cancer</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>124</volume>
            <issue>12</issue>
            <fpage>1949</fpage>
            <page-range>1949-1958</page-range>
            <pub-id pub-id-type="pmid">33828260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadoyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sakaeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okuno</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.</article-title>
            <source>Int J Med Sci</source>
            <year>2012</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-9</page-range>
            <pub-id pub-id-type="pmid">22211087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shakhbazova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marsch</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature.</article-title>
            <source>Dermatol Online J</source>
            <year>2019</year>
            <month>Nov</month>
            <day>15</day>
            <volume>25</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">32045142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sara</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khodadadi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lobo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lerman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grothey</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>5-fluorouracil and cardiotoxicity: a review.</article-title>
            <source>Ther Adv Med Oncol</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>1758835918780140</fpage>
            <pub-id pub-id-type="pmid">29977352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ihoriya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsukahara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yumoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Naito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakao</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hyperammonemic encephalopathy in a patient receiving fluorouracil/oxaliplatin chemotherapy.</article-title>
            <source>Clin Case Rep</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>603</fpage>
            <page-range>603-605</page-range>
            <pub-id pub-id-type="pmid">29636922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teraishi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chikuba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nezu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takiue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chikuba</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6].</article-title>
            <source>Gan To Kagaku Ryoho</source>
            <year>2009</year>
            <month>May</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>867</fpage>
            <page-range>867-9</page-range>
            <pub-id pub-id-type="pmid">19461197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yi</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy.</article-title>
            <source>Ann Surg Treat Res</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-82</page-range>
            <pub-id pub-id-type="pmid">26942162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Was</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Borkowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bagues</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JYH</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rudd</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Nurgali</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abalo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Chemotherapy-Induced Neurotoxicity.</article-title>
            <source>Front Pharmacol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>750507</fpage>
            <pub-id pub-id-type="pmid">35418856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jules</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thaper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ameli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pizzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Babi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Maciel</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Busl</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>5-Fluorouracil Neurotoxicity in the Absence of Dihydropyrimidine Dehydrogenase Deficiency Case Report.</article-title>
            <source>Neurohospitalist</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>366</fpage>
            <page-range>366-370</page-range>
            <pub-id pub-id-type="pmid">35419161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jose</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Joel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Selvakumar</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ramireddy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Georgy</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series.</article-title>
            <source>J Egypt Natl Canc Inst</source>
            <year>2022</year>
            <month>May</month>
            <day>23</day>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">35599280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hand-foot syndrome related to chemotherapy.</article-title>
            <source>CMAJ</source>
            <year>2012</year>
            <month>Oct</month>
            <day>16</day>
            <volume>184</volume>
            <issue>15</issue>
            <fpage>E818</fpage>
            <pub-id pub-id-type="pmid">22508979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Glenny</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Worthington</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Littlewood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clarkson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Dec</month>
            <day>23</day>
            <volume>2015</volume>
            <issue>12</issue>
            <fpage>CD011552</fpage>
            <pub-id pub-id-type="pmid">26695736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tayag</surname>
                <given-names>JCS</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kokuba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shiohira</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Changes in Pharmacodynamic Parameters during Co-administration of 5-FU with Warfarin: A Retrospective Case Series.</article-title>
            <source>Biol Pharm Bull</source>
            <year>2022</year>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1101</fpage>
            <page-range>1101-1105</page-range>
            <pub-id pub-id-type="pmid">35908892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Beumer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring of 5-fluorouracil.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-64</page-range>
            <pub-id pub-id-type="pmid">27217046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoshida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hiratsuka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aisu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kojima</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tanimura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ogata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mogi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takamatsu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mishima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method.</article-title>
            <source>Anticancer Res</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>4881</fpage>
            <page-range>4881-7</page-range>
            <pub-id pub-id-type="pmid">26254383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r42">
          <label>42</label>
          <element-citation publication-type="book">
            <chapter-title>Fluorouracil</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">31644088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traynor</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>FDA approves therapy to treat overdose of fluorouracil, capecitabine.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2016</year>
            <month>Feb</month>
            <day>01</day>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>100</fpage>
            <page-range>100, 102</page-range>
            <pub-id pub-id-type="pmid">26796900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Saif</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>El-Rayes</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Fakih</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Cartwright</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Posey</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>von Borstel</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Bamat</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>123</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-356</page-range>
            <pub-id pub-id-type="pmid">27622829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korgavkar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Weinstock</surname>
                <given-names>MA</given-names>
              </name>
              <collab>Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group</collab>
            </person-group>
            <article-title>Effect of Topical Fluorouracil Cream on Photodamage: Secondary Analysis of a Randomized Clinical Trial.</article-title>
            <source>JAMA Dermatol</source>
            <year>2017</year>
            <month>Nov</month>
            <day>01</day>
            <volume>153</volume>
            <issue>11</issue>
            <fpage>1142</fpage>
            <page-range>1142-1146</page-range>
            <pub-id pub-id-type="pmid">28877312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metterle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>552</fpage>
            <page-range>552-7</page-range>
            <pub-id pub-id-type="pmid">26577512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21848.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kumari</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Intralesional Triamcinolone Acetonide, 5-Fluorouracil, and Their Combination in Treatment of Keloids.</article-title>
            <source>World J Plast Surg</source>
            <year>2018</year>
            <month>May</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>212</fpage>
            <page-range>212-219</page-range>
            <pub-id pub-id-type="pmid">30083505</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
